Arch Financial Statements From 2010 to 2025
| ARTH Stock | USD 0.18 0.03 14.29% |
Check Arch Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arch Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Arch financial statements analysis is a perfect complement when working with Arch Therapeutics Valuation or Volatility modules.
Arch |
Arch Therapeutics OTC Stock Shares Outstanding Analysis
Arch Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Arch Therapeutics Shares Outstanding | 249.94 M |
Most of Arch Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Arch Therapeutics has 249.94 M of shares currently outstending. This is 38.44% higher than that of the Health Care Equipment & Supplies sector and 133.9% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 56.29% higher than that of the company.
Arch Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arch Therapeutics's current stock value. Our valuation model uses many indicators to compare Arch Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arch Therapeutics competition to find correlations between indicators driving Arch Therapeutics's intrinsic value. More Info.Arch Therapeutics is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Arch Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arch Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Arch Therapeutics Financial Statements
Investors use fundamental indicators, such as Arch Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Arch Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Arch OTC Stock
Arch Therapeutics financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Therapeutics security.